Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy | Zendy

Juan Zhou | Zendy; Dong Wang | Zendy; Jihua Zheng | Zendy; Zhu Wang | Zendy; Bo Xie | Zendy; Weimin Zhang | Zendy

Open Access

Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy

Author(s) -

Juan Zhou,

Dong Wang,

Jihua Zheng,

Zhu Wang,

Bo Xie,

Weimin Zhang

Publication year - 2018

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.165866

Subject(s) - ercc1 , oncology , nasopharyngeal carcinoma , medicine , chemoradiotherapy , univariate analysis , cisplatin , proportional hazards model , predictive marker , survival analysis , radiation therapy , multivariate analysis , chemotherapy , cancer , biology , nucleotide excision repair , dna repair , gene , biochemistry

To investigate the ability of excision repair cross-complementation group 1 (ERCC1) protein to predict cisplatin-based concurrent chemoradiotherapy (CCRT) response in locoregionally advanced nasopharyngeal carcinoma (NPC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research